AbbVie to acquire Allergan for $63 billion

Abbvie

America’s AbbVie Inc has announced that it would acquire Botox-maker Allergan Plc.

The acquisition will be a cash-and-stock deal estimated at about $63 billion.

In the proposed deal, Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each share held, for a total consideration of $188.24 per Allergan share.